References
Taylor DO, Ensley RD, Olsen SL, Dunn D, et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant. 1994;13:571–582.
Gorospe EC. Chronic diarrhoea from mycophenolate mofetil-induced colitis. BMJ Case Rep. 2012;2012:bcr1220115344. https://doi.org/10.1136/bcr.122011.5344.
Goyal A, Salahuddin M, Govil Y. A unique case of mycophenolate induced colitis after 10 years of use. Case Rep Gastrointest Med. 2016;2016:3058407. https://doi.org/10.1155/2916/3058407.
Moroncini G, Benfaremo D, Mandolesi A, Gabrielli A. Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis. BMJ Case Rep. 2018. https://doi.org/10.1136/bcr-2018-224829.
Dall’Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011;23:454–458.
Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today. 2009;45:521–532.
Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006;8:R182.
Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation. 2005;80:S181–S190.
Wieland E, Shipkova M, Schellhaas U, Schutz E, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107–113.
Khoury N, Ammor M, Durrbach A, Kriaa F, et al. Diffuse colitis associated with mycophenolate mofetil treatment: apropos of 1 case. Nephrologie. 2000;21:437–439.
Endo H, Kondo Y, Kawagoe K, Ohya TR, et al. Lupus enteritis detected by capsule endoscopy. Intern Med. 2007;46:1621–1622.
Lee CK, Ahn MS, Lee EY, Shin JH, et al. Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis). Ann Rheum Dis. 2002;61:547–550.
Lian TY, Edwards CJ, Chan SP, Chng HH. Reversible acute gastrointestinal syndrome associated with active systemic lupus erythematosus in patients admitted to hospital. Lupus. 2003;12:612–616.
Kwok SK, Seo SH, Ju JH, Park KS, et al. Lupus enteritis: clinical characteristics, risk factor for relapse and association with anti-endothelial cell antibody. Lupus. 2007;16:803–809.
Cervera R, Espinosa G, Cordero A, Oltra MR, et al. Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. Semin Arthritis Rheum. 2007;36:287–296.
Helliwell TR, Flook D, Whitworth J, Day DW. Arteritis and venulitis in systemic lupus erythematosus resulting in massive lower intestinal haemorrhage. Histopathology. 1985;9:1103–1113.
Calmet FH, Yarur AJ, Pukazhendhi G, Ahmad J. Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation. Ann Gastroenterol. 2015;28:366–373.
de Andrade LG, Rodrigues MA, Romeiro FG, Garcia PD, et al. Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients. Clin Transplant. 2014;28:1244–1248.
Selbst MK, Ahrens WA, Robert ME, Friedman A, et al. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol. 2009;22:737–743.
Liapis G, Boletis J, Skalioti C, Bamias G, et al. Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology. 2013;63:649–658.
Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transpl Proc. 2001;33:3238–3240.
Pescovitz MD, Conti D, Dunn J, Gonwa T, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant. 2000;14:179–188.
Perrin L, Giurgea I, Baudet-Bonneville V, Deschênes G, et al. Acute pancreatitis in paediatric systemic lupus erythematosus. Acta Paediatr. 2006;95:121–124.
Nesher G, Breuer GS, Temprano K, Moore TL, et al. Lupus-associated pancreatitis. Semin Arthritis Rheum. 2006;35:260–267. (review).
Cairoli E, Pérez G, Briva A, Cancela M, Alonso J. Fatal acute pancreatitis complicated by pancreatic pseudocysts in a patient with systemic lupus erythematosus. Rheumatol Int. 2010;30:675–678. https://doi.org/10.1007/s00296-009-0964-x. (Epub 2009 May 23).
Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol. 1999;10:833–839.
Einollahi B, Dolatimehr F. Acute pancreatitis induced by mycophenolate mofetil in a kidney transplant patient. J Nephropharmacol. 2015;4:72–74.
Sodikoff JB, Keilin SA, Cai Q, Bharmal SJ, et al. Mycophenolate mofetil for maintenance of remission in steroid-dependent autoimmune pancreatitis. World J Gastroenterol. 2012;18:2287–2290. https://doi.org/10.3748/wjg.v18.i18.2287.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paleti, S., Yarlagadda, B., Gremida, A. et al. Colitis and Pancreatitis in a Patient with Systemic Lupus Erythematosus: Due to Disease or to Drug?. Dig Dis Sci 63, 2206–2209 (2018). https://doi.org/10.1007/s10620-018-5225-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5225-y